|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:30296409 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases activity |
ISO |
veliparib results in increased phosphorylation of and results in increased activity of ATM protein veliparib results in increased activity of ATM protein |
CTD |
PMID:21917757 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] |
CTD |
PMID:18376143 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
affects response to substance decreases response to substance |
ISO |
BRCA1 affects the susceptibility to veliparib BRCA1 protein results in decreased susceptibility to veliparib |
CTD |
PMID:21633166 PMID:21707865 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
affects response to substance |
ISO |
BRCA2 affects the susceptibility to veliparib |
CTD |
PMID:21633166 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
affects response to substance |
ISO |
CDK12 protein affects the susceptibility to veliparib |
CTD |
PMID:27880910 |
|
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP1A2 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases metabolic processing |
ISO |
CYP2C19 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of veliparib |
CTD |
PMID:21436403 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases response to substance affects localization |
ISO |
EGFR protein results in decreased susceptibility to veliparib veliparib affects the localization of EGFR protein |
CTD |
PMID:21719137 PMID:21912620 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions |
ISO |
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions |
ISO |
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions |
ISO |
veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate] |
CTD |
PMID:25136123 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
[veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form |
CTD |
PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions |
ISO |
MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide] |
CTD |
PMID:21377995 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases response to substance |
ISO |
MRE11 protein results in decreased susceptibility to veliparib |
CTD |
PMID:21300766 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases activity increases expression |
ISO |
PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] veliparib results in decreased activity of PARP1 protein [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form |
CTD |
PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 PMID:21917757 PMID:22041887 PMID:22158865 PMID:27694308 PMID:28001384 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp10 |
poly (ADP-ribose) polymerase family, member 10 |
affects binding |
ISO |
veliparib binds to PARP10 protein |
CTD |
PMID:28001384 |
|
NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
affects binding decreases activity multiple interactions |
ISO |
PARP2 protein binds to veliparib veliparib results in decreased activity of PARP2 protein veliparib binds to and results in decreased activity of PARP2 protein |
CTD |
PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pten |
phosphatase and tensin homolog |
decreases response to substance |
ISO |
PTEN protein results in decreased susceptibility to veliparib |
CTD |
PMID:20530668 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rpa2 |
replication protein A2 |
multiple interactions |
ISO |
veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] |
CTD |
PMID:27694308 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:27444121 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
multiple interactions |
ISO |
TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions |
ISO |
veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD] |
CTD |
PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|